



## **Chembio Diagnostics to Report Third Quarter 2020 Financial Results on November 5, 2020**

October 23, 2020

HAUPPAUGE, N.Y., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter 2020 after the close of trading on Thursday, November 5, 2020.

The company's management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 844-602-0380 from the US or 862-298-0970 from outside the US or by accessing [www.chembio.com/investors/calendar-of-events/](http://www.chembio.com/investors/calendar-of-events/). A replay of the call will be available by dialing 877-481-4010 from the US or 919-882-2331 from outside the US (using passcode 38202) or by accessing [www.chembio.com/investors/calendar-of-events/](http://www.chembio.com/investors/calendar-of-events/).

### **About Chembio Diagnostics**

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at [www.chembio.com](http://www.chembio.com).

*DPP is Chembio's registered trademark. For convenience, this trademark appears in this release without ® symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the trademark.*

### **Investor contact:**

Philip Taylor  
Gilmartin Group  
(415) 937-5406  
[investor@chembio.com](mailto:investor@chembio.com)



Source: Chembio Diagnostics, Inc.